FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy
The FDA granted the approval for Genglycos based on a 48-week Phase III study involving 46 participants.
Drug Development
SandboxAQ introduces AQPotency for virtual drug screening
Andelyn Biosciences to develop GM2 gangliosidosis therapy
BeOne Medicines and partners renew Brukinsa access programme for CLL
Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status
Fulcrum and Slate Medicines sign merger agreement
EMA validates Pfizer and Valneva’s Lyme disease vaccine
FDA grants fast track status to Phanes’ spevatamig for advanced BTC
